Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin

Shinichi Komiyama, Takashi Kurahashi, Mitsuya Ishikawa, Kyoko Tanaka, Mizuka Komiyama, Mikio Mikami, Yasuhiro Udagawa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

It has been suggested that expression of TGFβ1 and its receptors [TGFβ receptor type I (TβRI) and TGFβ receptor type II (TβRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFβ1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFβ1, TβRI, and TβRII mRNA was assessed by the RNase protection assay. It was found that TGFβ1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGFβ1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. TβRI mRNA expression was not associated with any clinicopathological factors. Expression of TβRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGFβ1, TβRI, and TβRII, expression of TGFβ1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGFβl mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGFβ1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer.

Original languageEnglish
Pages (from-to)1131-1138
Number of pages8
JournalOncology Reports
Volume25
Issue number4
DOIs
Publication statusPublished - 2011 Apr

Fingerprint

Carboplatin
Paclitaxel
Ovarian Neoplasms
Neoplasms
Messenger RNA
Fallopian Tube Neoplasms
Clear Cell Adenocarcinoma
Endometrioid Carcinoma
Mucinous Adenocarcinoma
Ribonucleases
Disease-Free Survival
Adenocarcinoma

Keywords

  • Biomarker
  • Carboplatin
  • Ovarian cancer
  • Paclitaxel
  • Prognosis
  • TGFβ receptor
  • TGFβ1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. / Komiyama, Shinichi; Kurahashi, Takashi; Ishikawa, Mitsuya; Tanaka, Kyoko; Komiyama, Mizuka; Mikami, Mikio; Udagawa, Yasuhiro.

In: Oncology Reports, Vol. 25, No. 4, 04.2011, p. 1131-1138.

Research output: Contribution to journalArticle

Komiyama, S, Kurahashi, T, Ishikawa, M, Tanaka, K, Komiyama, M, Mikami, M & Udagawa, Y 2011, 'Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin', Oncology Reports, vol. 25, no. 4, pp. 1131-1138. https://doi.org/10.3892/or.2011.1151
Komiyama, Shinichi ; Kurahashi, Takashi ; Ishikawa, Mitsuya ; Tanaka, Kyoko ; Komiyama, Mizuka ; Mikami, Mikio ; Udagawa, Yasuhiro. / Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. In: Oncology Reports. 2011 ; Vol. 25, No. 4. pp. 1131-1138.
@article{d82a0209c1e4425a975104bf00e289bb,
title = "Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin",
abstract = "It has been suggested that expression of TGFβ1 and its receptors [TGFβ receptor type I (TβRI) and TGFβ receptor type II (TβRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFβ1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFβ1, TβRI, and TβRII mRNA was assessed by the RNase protection assay. It was found that TGFβ1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGFβ1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. TβRI mRNA expression was not associated with any clinicopathological factors. Expression of TβRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGFβ1, TβRI, and TβRII, expression of TGFβ1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGFβl mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGFβ1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer.",
keywords = "Biomarker, Carboplatin, Ovarian cancer, Paclitaxel, Prognosis, TGFβ receptor, TGFβ1",
author = "Shinichi Komiyama and Takashi Kurahashi and Mitsuya Ishikawa and Kyoko Tanaka and Mizuka Komiyama and Mikio Mikami and Yasuhiro Udagawa",
year = "2011",
month = "4",
doi = "10.3892/or.2011.1151",
language = "English",
volume = "25",
pages = "1131--1138",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin

AU - Komiyama, Shinichi

AU - Kurahashi, Takashi

AU - Ishikawa, Mitsuya

AU - Tanaka, Kyoko

AU - Komiyama, Mizuka

AU - Mikami, Mikio

AU - Udagawa, Yasuhiro

PY - 2011/4

Y1 - 2011/4

N2 - It has been suggested that expression of TGFβ1 and its receptors [TGFβ receptor type I (TβRI) and TGFβ receptor type II (TβRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFβ1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFβ1, TβRI, and TβRII mRNA was assessed by the RNase protection assay. It was found that TGFβ1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGFβ1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. TβRI mRNA expression was not associated with any clinicopathological factors. Expression of TβRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGFβ1, TβRI, and TβRII, expression of TGFβ1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGFβl mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGFβ1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer.

AB - It has been suggested that expression of TGFβ1 and its receptors [TGFβ receptor type I (TβRI) and TGFβ receptor type II (TβRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFβ1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFβ1, TβRI, and TβRII mRNA was assessed by the RNase protection assay. It was found that TGFβ1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGFβ1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. TβRI mRNA expression was not associated with any clinicopathological factors. Expression of TβRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGFβ1, TβRI, and TβRII, expression of TGFβ1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGFβl mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGFβ1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer.

KW - Biomarker

KW - Carboplatin

KW - Ovarian cancer

KW - Paclitaxel

KW - Prognosis

KW - TGFβ receptor

KW - TGFβ1

UR - http://www.scopus.com/inward/record.url?scp=79952209001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952209001&partnerID=8YFLogxK

U2 - 10.3892/or.2011.1151

DO - 10.3892/or.2011.1151

M3 - Article

VL - 25

SP - 1131

EP - 1138

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -